CAPR - Capricor Therapeutics, Inc.
1.12 +0.04 (3.70%)
After hours: 6:24PM EDT
| Previous Close | 1.12 |
| Open | 1.12 |
| Bid | 1.03 x 1000 |
| Ask | 1.12 x 1300 |
| Day's Range | 1.07 - 1.14 |
| 52 Week Range | 0.97 - 4.25 |
| Volume | 170,938 |
| Avg. Volume | 185,484 |
| Market Cap | 33.209M |
| Beta | 2.18 |
| PE Ratio (TTM) | 18.31 |
| EPS (TTM) | 0.06 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.80 |
- Simply Wall St.•8 days ago
S Spotlight On Capricor Therapeutics Inc’s (NASDAQ:CAPR) Fundamentals
I’ve been keeping an eye on Capricor Therapeutics Inc (NASDAQ:CAPR) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believeRead More...
- GlobeNewswire•last month
New Research Coverage Highlights Live Nation Entertainment, LightPath Technologies, Synchronoss Technologies, Mallinckrodt public limited company, Capricor Therapeutics, and Mersana Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Live ...
- GlobeNewswire•last month
Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles
At the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (CAPR) presented research findings on the mechanism of action and the immunomodulatory capacities of CAP-2003, the company’s investigational therapy comprised of proprietary extracellular vesicles, including exosomes, which are derived from cardiosphere-derived cells (CDC-EVs). Capricor is developing CAP-2003 as a therapeutic platform for treating diseases involving inflammation and fibrosis. The Gordon Research Conference on Extracellular Vesicles is focused on cutting-edge research on the biogenesis, molecular composition, functions, physio-pathological roles and potential clinical applications of extracellular vesicles.
- Zacks•last month
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
Capricor (CAPR) delivered earnings and revenue surprises of -7.69% and -1.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Capricor: 2Q Earnings Snapshot
On a per-share basis, the Beverly Hills, California-based company said it had a loss of 14 cents. The biotechnology company posted revenue of $404,000 in the period. In the final minutes of trading on ...
- GlobeNewswire•last month
Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
To Host Conference Call and Webcast Today at 4:30 p.m. ET. LOS ANGELES, Aug. 09, 2018-- Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological ...
- GlobeNewswire•2 months ago
Capricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9
Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its second quarter of 2018 financial results and corporate update shortly after the NASDAQ market close on Thursday, August 9. Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
- Benzinga•2 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) was trading lower by ...
- GlobeNewswire•2 months ago
Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
Capricor Therapeutics (CAPR) today announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to study the potential for the company’s next-generation investigational therapeutic platform, designated CAP-2003, which represents extracelluar vesicles (e.g., exosomes and microvesicles) to address a wide spectrum of trauma-related injuries and conditions, which are now the third leading cause of death in the U.S. CAP-2003 is derived from Capricor’s proprietary cardiosphere-derived cells (CDCs), which comprise adult cardiac progenitor cells from donor heart tissue. CAP-2003 has shown promising results in various pre-clinical experiments using established animal models of diseases by exerting anti-inflammatory, anti-fibrotic, pro-angiogenic, and anti-apoptotic effects.
- GlobeNewswire•2 months ago
Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18
Capricor Therapeutics (CAPR) and Parent Project Muscular Dystrophy (PPMD) will host a webinar at 1 p.m. ET on July 18 to provide information about the HOPE-2 clinical trial, which is evaluating the safety and efficacy of repeat doses of CAP-1002 in boys and young men with Duchenne muscular dystrophy and reduced upper limb function. An earlier clinical trial, HOPE-Duchenne, found a single intracoronary dose of CAP-1002 in participants in advanced stages of Duchenne muscular dystrophy was generally safe and well tolerated. “Please join PPMD and Capricor as we host this webinar to provide a brief background of CAP-1002 and its clinical development leading up to this exciting clinical trial,” said Linda Marbán, Ph.D., Capricor chief executive officer.
- GlobeNewswire•3 months ago
Capricor Therapeutics to Present at PPMD Annual Conference
Capricor Therapeutics’ (CAPR) chief medical officer, Deborah Ascheim, M.D., will present a corporate overview at the Parents Project Muscular Dystrophy (PPMD) 2018 Annual Conference on June 29 in Scottsdale, AZ. Capricor will also provide a poster presentation that will report pre-clinical data demonstrating the immunomodulatory capability of the company’s exosome product, CAP-2003, and the ability of this product to improve exercise capabilities in mdx mice after systemic administration.
- Simply Wall St.•3 months ago
Should You Be Holding Capricor Therapeutics Inc (NASDAQ:CAPR)?
Capricor Therapeutics Inc (NASDAQ:CAPR) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In theRead More...
- Simply Wall St.•4 months ago
Does Capricor Therapeutics Inc’s (NASDAQ:CAPR) PE Ratio Warrant A Buy?
Capricor Therapeutics Inc (NASDAQ:CAPR) is currently trading at a trailing P/E of 13.4x, which is lower than the industry average of 25.8x. While this makes CAPR appear like a greatRead More...
- Simply Wall St.•4 months ago
How Did Capricor Therapeutics Inc’s (NASDAQ:CAPR) 23.03% ROE Fare Against The Industry?
With an ROE of 23.03%, Capricor Therapeutics Inc (NASDAQ:CAPR) outpaced its own industry which delivered a less exciting 18.07% over the past year. Superficially, this looks great since we knowRead More...
- Associated Press•4 months ago
Capricor: 1Q Earnings Snapshot
On a per-share basis, the Beverly Hills, California-based company said it had a loss of 14 cents. The biotechnology company posted revenue of $400,100 in the period. Its adjusted revenue was $400,000. ...
- ACCESSWIRE•5 months ago
Wired News – Capricor’s New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy
LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Capricor Therapeutics, Inc. (NASDAQ: CAPR) ("Capricor"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CAPR as the Company's latest news hit the wire. On April 19, 2018, the Company announced that its pre-clinical study has established that repeated dosing of its lead candidate, CAP-1002, yields an increase in exercise performance in a disease model of Duchenne Muscular Dystrophy (DMD), the mdx mouse.
- ACCESSWIRE•6 months ago
Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018
LOS ANGELES, CA / ACCESSWIRE / April 6, 2018 / Capricor Therapeutics (NASDAQ: CAPR) today announces that AJ Bergmann, Chief Financial Officer will be a featured presenter at the MicroCap Conference on ...
